Changes at AMRI
On Wednesday, the board of directors voted unanimously to separate the role of CEO and chairman. President and CEO Thomas D'Ambra, 57, has held the chairman role since co-founding the global company in 1991.
William S. Marth, an active member of the board since 2012, was named chairman of the board under the new arrangement. He was formerly the president and CEO of the North America and USA subsidiaries of Teva Pharmaceutical Industries Ltd., and currently serves as a senior adviser to the Israel-headquartered pharmaceutical company.
In addition, stockholders re-elected D'Ambra to serve another three-year term as a Class III director at the company's annual stockholders meeting held Wednesday at its corporate offices in Albany. Stockholders also re-elected Veronica G.H. Jordan to serve as a Class III director. She has served as a director since 2006, prior to which she held senior roles at Medelle Corporation, Parexel International Corporation, Biogen Incorporated and Baxter International.
Stockholders also ratified the company's selection of Albany firm KPMG LLP as its independent registered public accounting firm for the 2013 fiscal year, and approved an employee stock purchase plan, a stock option and incentive plan, and the compensation of AMRI's named executive officers.
AMRI is a contract research and manufacturing organization with locations in the U.S. and abroad. It provides drug discovery and scientific services, technologies and products to the pharmaceutical and biotechnology industries.
Follow @GazetteBiz on Twitter.